Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Preparation and Dissolution Characteristics of Sustained Release Pellets Containing Isosorbide Dinitrate

질산 이소소르비드가 함유된 서방형 펠렛의 제조 및 용출 특성

  • Lee, Gye-Won (Laboratory Of Galenic Technology, Department of Pharmaceutical Engineering, Konyang University) ;
  • Kim, Hak-Hyung (Laboratory Of Galenic Technology, Department of Pharmaceutical Engineering, Konyang University) ;
  • Ryu, Sung-Kyun (Laboratory Of Galenic Technology, Department of Pharmaceutical Engineering, Konyang University)
  • 이계원 (건양대학교 제약공학과 제제개발실) ;
  • 김학형 (건양대학교 제약공학과 제제개발실) ;
  • 유성균 (건양대학교 제약공학과 제제개발실)
  • Published : 2008.12.20
Download PDF
⟨ Previous Next ⟩

Abstract

Isosorbide dinitrate is an oral assiatant therapy agent of angina pectoris, myocardial infarction and congestive heart failure. The objective of this study was to formulate sustained release containing isosorbide dinitrate and assess their formulation variables. Pellets were prepared by fluid bed process and consist of drug layer and membrane layer. The pellets were coated with ethylcellulose along with $5{\sim}15%$ of plasticizer such as triacetin and diethyl butylrate. In vitro evaluation study was performed by comparative dissolution test between test and reference isosorbide dinitrate preparation. We could prepare sustained pellets of isosorbide dinitrate by fluid bed process which were reduced process time and had high content. The pellet coated with 1% ethylcellulose and triacetin(l5%) had a similar dissolution behavior compare to reference isosorbide dinitrate preparation controlling initial dissolution and those of dissolution at 30 min were 17.25 and 17.09%, respectively. Difference factor and similarity factor were $0{\sim}15$ and $50{\sim}100$ and there was no significant difference in bioequivalence between formulations. It might be concluded that our sustained release pellet of isosorbide dinitrate could be an alternatively delivery system to reference drug preparation.

Keywords

References

  1. J. S. Kim and etc., Sustained release pellet of isosorbide dinitrate, KR10-2001-0068947 (2004)
  2. F. Sadeghi, J. L. Ford and A. Tajabi-Siahboomi, The influence of drug type on release profiles from sustained release-coated pellet, Int. J. Pharm., 254, 123-135 (2003) https://doi.org/10.1016/S0378-5173(03)00003-6
  3. A. Dashevsky, K. Wagner and R. Bodmeier, pH-independent release of a basic drug from pellets coated with the extended release polymer dispersion Kollicoat SR 30D and enteric polymer dispersion Kollicoat MAE 30DP, Eur. J. Pharm. Biopharm., 58, 45-49 (2004) https://doi.org/10.1016/j.ejpb.2004.03.013
  4. A. Dashevsky, K. Wagner, K. Kolter and R. Bodmeier, Physicochemical and release properties of pellet coated with Kollicoat$^{\circledR}$ SR 30D, a new aqueous polyvinyl acetate dispersion for extended release, Int. J. Pharm., 290, 15-23 (2005). https://doi.org/10.1016/j.ijpharm.2004.10.024
  5. H. H. Kim, J. H. Oh and K. Han, A formulation study for the controlled release rate of diltiazemHCl using the multiple drug release system, J. Kor. Pharm. Sci., 35(3), 157-163 (2005).
  6. J. S. Park, J. A. Seo, S. Y. Jeong, S. H. Yuk, B. C. Shin, S. J Hwang and S. H. Cho, Formulation of sustained release granule for venlafaxineHCl using water-insoluble polymer, J. Kor. Pharm. Sci., 37(2), 101-106 (2007)
  7. FDA, Guidance for industry : Immediat release solid oral dosage form - scale-up and post approval changes : Chemistry, manufacturing and controls : in vitro dissolution testing and in vivo bioequivalence documentation, Canter for drug evaluation and research, rockville, MD November, 1995
  8. FDA, Guidance for industry : Dissolution testing of immediate release solid oral dosage forms, Center for drug evaluation and research, Rockville, MD August, 1997a
  9. FDA guidance for industry, SUPAC-MR : modified release solid oral dosage forms; scale-up and post approval changes; chemistry, manufacturing and controls; In vitro dissolution testing and in vivo bioequivalence documentation, MD September, 1997b
  10. V. P. Shah, Y. Tsong, P. Sathe and J. P. Liu, In vitro dissolution profile comparison-statistics and analysis of similarity factor, F2, Pharm. Res., 15(6), 889 (1998) https://doi.org/10.1023/A:1011976615750
  11. J. W. Moore and H. H. Flanner, Mathematical comparison of curves with an emphasis on in vitro dissolution profiles, Pharm. Tech., 20(6), 64 (1996)
  12. M. Choi, C. S. Kang, B. K. Choi, C. H. Hong and K. S. Kim, In vitro/in vivo correlation of sustained release ditiazem, J. Kor. Pharm. Sci., 32(4), 321-325 (2002)